REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
15/02/2026
Voltar para busca
Dado oficial do USPTO
ADLIB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
16/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
28/04/2015
Data de registro
14/02/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/06/2023
Última transação
16/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Tokyo, JP
Examinador
MAHONEY, PAULA M
Unidade examinadora
N10
Titulares e representantes
Titulares
Chiome Bioscience Inc.
Representantes
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Monoclonal antibodies for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; peptides and proteins for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicines for human purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicines for dental purposesfor infectious diseasesneurological diseases or inflammatory diseases; medicines for veterinary purposesfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; medicinal preparationsfor oncologicalviralinfectiousendocrinemetabolicneurologicalcardiovascularhematologicalcardiopulmonaryrespiratorymusculoskeletalrenalhepatologicalgastrointestinalgenitourinaryophthalmicdermatologicalimmune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposesfor cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implantsa vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin
Classe 42
Researchproduct development and quality control services in the field of proteinsantibodiesmicroorganisms and cellsconsultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products * Researchproduct development and quality control services in the field of proteinsantibodiesmicroorganisms and cellsconsultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals *
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
24/04/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/04/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
01/04/2024
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
26/02/2024
INPC
INVALIDATION PROCESSED
26/02/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/02/2024
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
10/06/2023
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
10/06/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
29/05/2023
ES71
TEAS SECTION 71 RECEIVED
15/11/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
14/02/2022
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
07/03/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
23/02/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/10/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/09/2017
FIMP
FINAL DISPOSITION PROCESSED
15/09/2017
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/08/2017
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
23/06/2017
PLGL
ASSIGNED TO PARALEGAL
06/06/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/05/2017
ES7R
TEAS SECTION 7 REQUEST RECEIVED
09/03/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
14/02/2017
CHPN
POST PUBLICATION AMENDMENT – NOT ENTERED
01/02/2017
APET
ASSIGNED TO PETITION STAFF
31/01/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/12/2016
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
28/12/2016
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
16/12/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
16/12/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/11/2016
PUBO
PUBLISHED FOR OPPOSITION
29/11/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/11/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/11/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/11/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
27/10/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/10/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/09/2016
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
23/09/2016
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
19/09/2016
ALIE
ASSIGNED TO LIE
15/09/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/03/2016
GNSL
LETTER OF SUSPENSION E-MAILED
10/03/2016
CNSL
SUSPENSION LETTER WRITTEN
10/03/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/02/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/02/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/02/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/02/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/02/2016
RFNT
REFUSAL PROCESSED BY IB
04/09/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/08/2015
RFRR
REFUSAL PROCESSED BY MPU
14/08/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/08/2015
CNRT
NON-FINAL ACTION WRITTEN
13/08/2015
DOCK
ASSIGNED TO EXAMINER
08/08/2015
MAFR
APPLICATION FILING RECEIPT MAILED
29/07/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/07/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/07/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ADLIB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.